Abstract:
Introduction. Globally, UTIs rank as a leading type of bacterial infection, commonly demanding clinical attention and antimicrobial therapy. Recent estimates reveal that nearly 150 million individuals develop urinary tract infections each year. Among uropathogens, Escherichia coli prevails, accounting for broadly % of community-associated urinary infections. Widespread and improper antibiotic use has driven E.coli resistance, emphasizing the significance of susceptibility testing to steer rational treatment and constraint resistance spread. Aim of study. This study intends to evaluate the current antimicrobial susceptibility of uropathogenic E.coli strains isolated from urine cultures, based on a review of recent scientific literature and laboratory findings. The findings aim to support enhanced therapy and resistance control. Methods and materials. This research was directed through a review of scientific literature published over the last ten years (2016-2026). Relevant sources were retrieved from: PubMed, Google Scholar, ResearchGate, the WHO website, and peer-reviewed journals including the Polish Journal of Microbiology, Materia Socio-Medica, and the Romanian Journal of Infectious Diseases. A total of 34 articles were selected and analyzed. Results. Current studies confirm the prevalence of E.coli among uropathogens in both community- and hospital-acquired UTIs, accounting for 70-80% of cases. Resistance profiles varied by antibiotic and region. High susceptibility was recorded for amikacin (>80%), carbapenems (>80%), and nitrofurantoin (75-90%). Conversely, elevated resistance was stated for ampicillin (up to 82%), amoxicillin-clavulanic acid (40-52%), co-trimoxazole (34-45%), fluoroquinolones (ciprofloxacin 9-32%). ESBL-producing strains were reported in 2-30% of isolates, with multidrug-resistant (MDR) strains reaching 50-70% in specific populations. Resistance was higher in hospitalized patients, older adults (>50 years), males, and subjects with prior antibiotic exposure. Virulence factors (fimH, pap, cnfl, hlyA) were frequently linked to resistance and complex infections. These results underscore the significance of local susceptibility data and persistent monitoring to guide empirical therapy and limit the spread of resistant strains. Conclusions. The outcomes illustrate an increasing level of antimicrobial resistance among urinary E.coli isolates, especially to commonly prescribed antibiotics and rising reports of MDR and ESBL-producing strains. Sustained susceptibility to nitrofurantoin, amikacin, and carbapenems supports the requirement for evidence-based empirical treatment directed by local antimicrobial susceptibility data.